Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma

References

• Cox D. R., Snell E. J. Analysis of Binary Data, 23rd Edition. Methuen, London 1989; 159–161
   Google Scholar
• D'Oleire F., Schmitt C. L., Robins H. I., Cohen J. D., Spriggs D. Cytokine induction in humans during 41·8°C whole body hyperthermia. Journal of the National Cancer Institute 1993; 85: 833–834
   PubMedGoogle Scholar
• Dewhirst M. W. Factors influencing hyperthermic enhancement of drug cytotoxicity. International Journal of Radiation Oncology, Biology and Physics 1993; 25: 569–570
   PubMedGoogle Scholar
• Engelhardt R. Hyperthermia and drugs. Recent Results in Cancer Research 1987; 104: 136–203
   PubMedGoogle Scholar
• Engelhardt R. Summary of recent clinical experience in whole-body hyperthermia combined with chemotherapy. Recent Results in Cancer Research 1988; 107: 200–204
   PubMedGoogle Scholar
• Faulds D., Balfour J. A., Chrisp P., Langtry H. D. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1992; 47: 400–449
   Google Scholar
• Gerad H., van Echo D. A., Whitacre M., Ashman M., Helrich M., Foy J., Ostrow S., Wiernik P. H., Aisner J. Doxorubicin, cyclophosphamide, and whole body hyperthermia for treatment of advanced soft tissue sarcoma. Cancer 1984; 53: 2585–2591
   PubMed Web of Science ®Google Scholar
• Greenlee P. G., Filippa D. A., Quimby F. W., Patnaik A. K., Calvano S. E., Matus R. E., Kimmel M., Hurvitz A. I., Lieberman P. H. Lymphomas in dogs. A morphologic, and clinical study. Cancer 1990; 66: 480–490
   PubMed Web of Science ®Google Scholar
• Herman T. S. Effect of temperature on the cytotoxicity of vindesine, amsacrine, and mitoxantrone. Cancer Treatment Reports 1983; 67: 1019–1022
   PubMedGoogle Scholar
• Herman T. S., Teicher B. A., Varshney A., Khandekar V., Brann T. Effect of hypoxia and acidosis on the cytotoxicity of mitoxantrone, bisantrene and amsacrine and their platinum complexes at normal and hyperthermic temperatures. Anticancer Research 1992; 12: 827–836
   PubMedGoogle Scholar
• Juvekar A. S., Chitnis M. P. Circumvention of drug resistance of P388/R cells by the combination of adriamycin and motoxantrone with hyperthermia (42°C). Neoplasma 1991; 38: 207–211
   PubMedGoogle Scholar
• Juvekar A. S., Chitnis M. P., Adwankar M. K., Advani S. H. Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia. Neoplasma 1986; 33: 477–482
   PubMedGoogle Scholar
• Juvekar A. S., Chitnis M. P., Advani S. H. In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells. Neoplasma 1987; 34: 199–204
   PubMedGoogle Scholar
• Kim Y. D., Lees D. E., Lake C. R., Whang-Peng J., Schuette W., Smith R., Bull J. Hyperthermia potentiates doxorubicin-related cardiotoxic effects. Journal of the American Medical Association 1979; 241: 1816–1817
   PubMed Web of Science ®Google Scholar
• Moore A. S., Ogilvie G. K., Ruslander D., Rand W. S., Cotter S. M., Getzy D. M., L'Heureux D. A., Dennis R. A. Evaluation of mitoxantrone for the treatment of lymphoma in dogs. Journal of the American Veterinary Medical Association 1994; 205: 1903–1905
   Google Scholar
• O'Quigley J. Sequential design and analysis of dose finding studies in patients with life threatening disease. Fundamentals of Clinical Pharmacology 1990; 4(Supplement 2)81s–91s
   Google Scholar
• Ogilvie G. K., Obradovich J. E., Elmslie R. E., Vail D. M., Moore A. S., Straw R. C., Dickinson K., Cooper M. F., Withrow S. J. Efficacy of mitoxantrone against various neoplasms in dogs. Journal of the American Veterinary Medical Association 1991; 198: 1618–1621
   PubMed Web of Science ®Google Scholar
• Ogilvie G. K., Moore A. S., Chen C., Ciekot P. A., Atwater S. W., Bergman P. J., Walters L. M. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: A dose escalation study. Journal of the American Veterinary Medical Association 1994; 205: 570–573
   PubMedGoogle Scholar
• Ohno S., Strebel F. R., Stephens L. C., Siddik Z. H., Baba H., Makino M., Khokhar A. R., Bull J. M. C. Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. British Journal of Cancer 1993; 68: 469–474
   PubMed Web of Science ®Google Scholar
• Ohnoshi T., Ohnuma T., Beranek J. T., Holland J. F. Combined cytotoxicity effect of hyperthermia and anthracycline antibiotics on human tumor cells. Journal of the National Cancer Institute 1985; 74: 275–281
   PubMedGoogle Scholar
• Owen L. N. TNS Classification of Tumors in Domestic Animals WHO. GenevaSwitzerland 1980
   Google Scholar
• Page R. L., Meyer R. E., Thrall D. E., Dewhirst M. W. Cardiovascular and metabolic response of tumour-bearing dogs to whole body hyperthermia. International Journal of Hyperthermia 1987; 3: 513–525
   PubMed Web of Science ®Google Scholar
• Page R. L., Thrall D. E., Dewhirst M. W., Macy D. W., George S. L., McEntee M. C., Heidner G. L., Novotney C. A., Allen S. A., Withrow S. J., Gillette E. L. Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. International Journal of Hyperthermia 1991; 7: 559–566
   PubMed Web of Science ®Google Scholar
• Page R. L., Thrall D. E., George S. L., Price G. S., Heidner G. L., McEntee M. C., Novotney C. A., Hauck M. L., Dewhirst M. W. Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumour-bearing dogs. International Journal of Hyperthermia 1992a; 8: 761–769
   PubMed Web of Science ®Google Scholar
• Page R. L., Macy D. W., Ogilvie G. K., Rosner G. L., Dewhirst M. W., Thrall D. E., Withrow S. J., McEntee M. C., Cline J. M., Heidner G. L., Novotney C. A., Gillette E. L. Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. International Journal of Hyperthermia 1992b; 8: 187–197
   PubMed Web of Science ®Google Scholar
• Page R. L., McEntee M. C., Williams P. L., George S. L., Price G. S., Novotney C. A., Hauck M. L., Riviere J. E., Dewhirst M. W., Thrall D. E. Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs. International Journal of Hyperthermia 1994, (in press)
   Google Scholar
• Page R. L., Thrall D. E. Therapeutic hyperthermia: contributions from clinical studies in dogs with spontaneous neoplasia. 1994, In vivo, (in press)
   Google Scholar
• Robins H. I., Longo W. L., Steeves R. A., Cohen J. D., Schmitt C. L., Neville A. J., O'Keefe S., Logoni R., Riggs C. Adjunctive therapy (whole body hyperthermia versis lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations. International Journal of Radiation Oncology, Biology and Physics 1990; 18: 909–920
   PubMed Web of Science ®Google Scholar
• Robins H. I., Cohen J. D., Schmitt C. L., Tutsch K. D., Feierabend C., Arzoomanian R. Z., D'Oliere F., Longo W., Heiss C., Rushing D., Love R., Spriggs D. Phase I clinical trial of carboplatin and 41·8°C whole-body hyperthermia in cancer patients. Journal of Clinical Oncology 1993; 11: 1787–1794
   PubMed Web of Science ®Google Scholar
• Robins H. I., Kutz M., Wiedemann G. J., Katschinski D. M., Paul D., Crosen E., Tiggelaar C. L., Spriggs D., Gillis W., D'Oleire F. Cytokine induction by 41·8°C whole body hyperthermia. Cancer Letters 1995, (in press)
   Google Scholar
• Shen R. N., Hornback N. B., Shidnia H., Wu B., Lu L., Broxmeyer H. E. Whole body hyperthermia: a potent radioprotecto in vivo. International Journal of Radiation Oncology Biology and Physics 1991; 20: 525–530
   PubMed Web of Science ®Google Scholar
• Smith I. E. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treatment Reviews 1983; 10: 103–115
   PubMed Web of Science ®Google Scholar
• Storer B. E. Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925–937
   PubMed Web of Science ®Google Scholar
• Strother S. V., Bull J. M. C., Branham S. A. Activation of coagulation during therapeutic whole body hyperthermia. Thrombosis Research 1986; 43: 353–360
   PubMedGoogle Scholar
• Teske E. Non-Hodgkin's lymphoma in the dog: characterization and experimental therapy. PhD Thesis, University of Utrecht. 1993
   Google Scholar
• Thrall D. E., Page R. L., Dewhirst M. W., Meyer R. E., Hoopes P. J., Kornegay J. N. Temperature measurements in normal and tumor tissue of dogs undergoing whole body hyperthermia. Cancer Research 1986; 46: 6229–6235
   PubMed Web of Science ®Google Scholar
• Urano M., Reynolds R., Begley J. No thermal enhancement of adriamycin cytotoxicity. Proceedings of the 11th annual meeting of the North American Hyperthermia Group. 1991, (abstr)
   Google Scholar
• Wang B. S., Lumanglas A. L., Silva J., Ruszala-Mallon V. M., Durr F. E. Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone. Cancer Treatment Reports 1987; 71: 831–836
   PubMedGoogle Scholar
• Wiedemann G., Mella O., Roszinski S., Weiss C., Wagner T. Hyperthermia enhances mitoxantrone cytotoxicity on human breast carcinoma and sarcoma xenografts in nude mice. International Journal of Radiation Oncology, Biology and Physics 1992; 24: 669–673
   PubMed Web of Science ®Google Scholar
• Woods J. P., Schmitt-Tiggelaar C. L., d'Oleire F., Rosenthal R., Robins H. I. Hematological effect of radiant heat-induced whole body hyperthermia on dogs. Canadian Journal of Veterinary Research 1995, (in press)
   Google Scholar
• Yang S., Rafla S. Temperature effect on mitoxantrone cytotoxicity in Chinese hamster cell in vitro. Cancer Research 1985; 45: 3593–3597
   PubMedGoogle Scholar